- Home
- NRIX vs MUC Comparison
NRIX vs MUC Comparison
Compare NRIX & MUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- MUC
- Stock Information
- Founded
- NRIX 2009
- MUC 1997
- Country
- NRIX United States
- MUC United States
- Employees
- NRIX N/A
- MUC N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- MUC Investment Bankers/Brokers/Service
- Sector
- NRIX Health Care
- MUC Finance
- Exchange
- NRIX Nasdaq
- MUC Nasdaq
- Market Cap
- NRIX 1.1B
- MUC 1.0B
- IPO Year
- NRIX 2020
- MUC N/A
- Fundamental
- Price
- NRIX $10.47
- MUC $10.82
- Analyst Decision
- NRIX Strong Buy
- MUC
- Analyst Count
- NRIX 17
- MUC 0
- Target Price
- NRIX $30.82
- MUC N/A
- AVG Volume (30 Days)
- NRIX 1.0M
- MUC 292.8K
- Earning Date
- NRIX 04-14-2025
- MUC 01-01-0001
- Dividend Yield
- NRIX N/A
- MUC 4.19%
- EPS Growth
- NRIX N/A
- MUC N/A
- EPS
- NRIX N/A
- MUC N/A
- Revenue
- NRIX $54,549,000.00
- MUC N/A
- Revenue This Year
- NRIX N/A
- MUC N/A
- Revenue Next Year
- NRIX $3.20
- MUC N/A
- P/E Ratio
- NRIX N/A
- MUC N/A
- Revenue Growth
- NRIX N/A
- MUC N/A
- 52 Week Low
- NRIX $10.37
- MUC $9.19
- 52 Week High
- NRIX $29.56
- MUC $11.30
- Technical
- Relative Strength Index (RSI)
- NRIX 23.27
- MUC 51.64
- Support Level
- NRIX $12.20
- MUC $10.61
- Resistance Level
- NRIX $13.10
- MUC $10.81
- Average True Range (ATR)
- NRIX 0.82
- MUC 0.09
- MACD
- NRIX -0.10
- MUC 0.00
- Stochastic Oscillator
- NRIX 2.33
- MUC 84.00
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About MUC Blackrock MuniHoldings California Quality Fund Inc.
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment firm. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes.